What drugs does SAGENT make?

SAGENT has 11 FDA-approved drugs including NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE.

What therapeutic areas does SAGENT focus on?

SAGENT focuses primarily on Gastroenterology and Cardiovascular and 1 other therapeutic areas.

← Back

Data updated: Jun 28, 2026

SAGENT

Generics

Gastroenterology Cardiovascular Neurology

SAGENT is a generic drug manufacturer focused on Gastroenterology, Cardiovascular, Neurology.

1995

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

SAGENT's Key Drugs

SAGENT's core commercial portfolio centers on NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, spanning Gastroenterology and Cardiovascular — its most strategically important drugs approved in the last 15 years.

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

Cardiovascular

Hypotension

alpha-adrenergic receptor Approved 2021

SAGENT's Recent FDA Approvals

SAGENT secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

SAGENT's Therapeutic Areas

SAGENT's approved drugs and pipeline span 3 therapeutic areas, led by Gastroenterology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 50%

2 drugs

Cardiovascular 25%

1 drugs

Neurology 25%

1 drugs

SAGENT's Top Competitors

SAGENT's closest competitors by therapeutic-area and drug-target overlap include VALIDUS PHARMS, WARNER CHILCOTT, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

VALIDUS PHARMS specialty

Cardiovascular, Gastroenterology, Neurology

WARNER CHILCOTT big-pharma

Cardiovascular, Gastroenterology, Neurology

Bristol-Myers Squibb big-pharma

Gastroenterology, Neurology

BAUSCH specialty

Cardiovascular, Gastroenterology

CHIESI big-pharma

Cardiovascular, Neurology, Gastroenterology